A man who discovered he had prostate cancer following a free blood test run by a volunteer group has urged other men to get ...

Illuccix has gained significant market share due to changes in clinical practice and successful distribution. The company requires minimal capital and is expected to generate very high returns as it ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics, today announced ...

“Partnering with John ‘Shrek’ McPhee, reinforces our commitment to making testosterone therapy accessible and effective,” said Marius Pharmaceuticals CEO Shalin Shah, adding, “With KYZATREX’s ...

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the latest real-world evidence with the Galleri® multi-cancer early ...

Firm Fratton favourites David Norris and Gary Roberts are the two latest former Pompey players who will be returning to the ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd ...

The first patient was dosed in the Phase 1 ZOLAR 7 trial of TLX300-CDx ( 89 Zr-olaratumab), which aims to validate the use of olaratumab, an antibody exclusively licensed from Eli Lilly and Company ...